Clin Mol Hepatol.
2025 Jan;31(1):293-296. 10.3350/cmh.2024.0703.
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
- Caddeo A1
- Mancina RM
2,3,4
- Affiliations
-
- 1Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy
- 2Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy
- 3Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden
- 4Research Unit of Clinical Medicine and Hepatology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy
- KMID: 2563433
- DOI: http://doi.org/10.3350/cmh.2024.0703
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
- TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
- Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan
- Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
- Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
